Study of Tamoxifen and Raloxifene (STAR)
Baptist Health continues to recruit participants for the second Breast Cancer
Prevention Trial, called the Study of Tamoxifen and Raloxifene (STAR). STAR
is comparing tamoxifen - found to reduce the incidence of breast cancer by 50%
in the first Breast Cancer Prevention Trial - to raloxifene. Raloxifene is a
drug approved by the FDA for the prevention of osteoporosis; there are reasons
to believe it may also prevent breast cancer. With a goal of recruiting 22,000
participants nationally, STAR will be the largest breast cancer study to date.
Those eligible for the study include all women over the age of 60 and also women
over the age of 35 who are postmenopausal. If a woman is determined to be eligible
to participate in the study, Baptist Cancer Institute will provide one of the
two medications and she will be followed with the basic monitoring required
to assure a woman's health such as periodic mammograms, physical exams, gynecologic
exams and blood tests. To find out if you are eligible for STAR or to help Baptist
Cancer Institute recruit participants in the community, please call (904) 202-7073.
For more information about this program please visit the National Surgical
Adjuvant Breast & Bowel Project at:
e-baptisthealth.com
